Upload
jasper-flynn
View
212
Download
0
Tags:
Embed Size (px)
Citation preview
Precise epidermal delivery
v20151005
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 2
BEST-IN-CLASS
LASER-ASSISTED
EPIDERMAL DRUG DELIVERY
EPIDRUG™ & EPIMMUN™
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 3
Company profile
Location Ruggell, Liechtenstein
Foundation 2005 Dec.
Key assets - proprietary technology in epidermal delivery of
immunogens and drugs- portfolio of granted patents
and patent applications- EPIMMUN™: promising pre-
clinical results for delivery of variety of immunogens
- EPIDRUG™: clinical proof of concept for several drugs
Investors Private investors, VC company
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 4
P.L.E.A.S.E. = Precise Laser EpidermAl System
The only existing Ablative Laser Class 1 Full delegation - to be used by non-doctoral staff
No safety precautions required
User-friendly interface for easy programming
Small and mobile for easy use
Precise and painless delivery
Patent protected
Medical CE marked
Pantec’s device – P.L.E.A.S.E. Professional
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 5
EPIDRUG™ and EPIMMUN™ allows for optimal, dose-
controlled delivery of various drug and immunogen
substances into targeted skin layers offering an optimal
safety profile and in case of EPIMMUN™ inducing an active
immune-response and triggering a laser adjuvant effect.
Applications– EPIDRUG™ & EPIMMUN™
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 6
Precise and reproducible formation of micropores in desired skin layer
Topical administration of substance
Efficient delivery of substance through micropores and uptake relevant immune cells or receptors
EPIMMUN™ and EPIDRUG™ Process
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 7
We love micro-Pores!
Laser-assisted generation of micropores – the basis of the P.L.E.A.S.E. platform
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 8
EPIMMUNTM EPIDRUG™
EPIMMUN™ and EPIDRUG ™ allow for precise, dose-controlled delivery of various substances into targeted skin layers, offering an optimal safety profile.
Precise epidermal delivery
+ Immune
stimulant effect; laser adjuvant effect
Precise epidermal delivery
P.L.E.A.S.E.Precise Laser
EpidermAl SystEm
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 9
Precise micropore depth - delivery to target skin layers
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 10
200 mm
60 mm
• Easy to use, needle-less, painless, well-tolerated
• Reproducible formation of micropores• Precise depth
• Desired skin layers
• Induction of strong immune response (EPIMMUN™ only)• Precise immunogen delivery to target immune cells
• Immune-stimulant effect
Key advantages of EPIMMUN™ and EPIDRUG™
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 11
Market and Fields of ApplicationOncology active Immunotherapy
WW sales in 2014 of $ 41 billion1
Cancer immunotherapy is „ breakthrough treatment of the year 2013“ Checkpoint inhibitors and their combination with cancer active immunotherapies will substantially
contribute to expected growth of the market High medical need for effective immunogen delivery to target immune cells
Preventive and therapeutic vaccines WW sales of $ 33 billion in 2014 expected to grow to $56 billion in 20192
Needle-less delivery systems are highly needed, particularly in the developing world
Allergy immunotherapy WW sales of $ 1,1 billion in 20143
Highly underserved market – only 2% of allergic patents are currently treated because of cumbersome treatment schedules (>50 injections) over long period (>3 years)
Autoimmune disease drugs WW sales expected at $ 61 billion in 20174
Unmet medical need for local targeted delivery (reduce side effects of systemic drug administration)
Combined market potential > $100 billion1 Global & USA Cancer Immunotherapy Market Analysis to 20202 Markets and Markets 2015, „Vaccine market by technology – Forecast to 20193 ALK, Annual Report 20144 GBI Research, Autoimmune Disorders Therapeutics Market to 2017
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 12
Business Model
Formation of partnerships with biotech and pharmaceutical companies for commercialization of combination products using EPIDRUG™ or EPIMMUNTM together with their proprietary drug or vaccine formulations
To achieve this objective, Pantec
will generate broad database of preclinical and clinical data with EPIDRUG™ and EPIMMUNTM in wide variety of indications in collaboration with (existing and newly formed) research partnerships with leading academic institutions and biotech companies
will use this database to convince pharma companies to combine their substances with EPIDRUG™ and EPIMMUNTM
will enter into licensing agreements with pharma partners in return for upfront and milestone fees as well as royalties
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 13
Revenue Generation
Sales of devices and consumables Short Term: Laser devices (and consumables) on rental or purchase basis for research
partners Mid Term: Sales of laser devices and consumables to clinical trial centers and pharma
companies conducting studies with partnered products
Cumulative sales revenues of ~ € 1,7 million projected until 2018 (2015: ~ € 500.000)
Long Term: After launch of partnered product(s) (first launch expected in 2019) substantial increase in sales of laser devices and consumables to end users (physicians)
Licensing revenues Upfront, Milestone and Royalty payments from pharma partners
Pantec has already signed three such licensing agreements with pharma and biotech companies
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 14
Financials – Financing RoundFinancing Volume: € 4 Million
Funding reach: end 2018
Use of Proceeds: Business development and marketing/sales activities to leading scientific research institutions
and biotech companies Support of research institutions to generate strong EPIDRUG™/EPIMMUNTM preclinical/clinical data
base Business development for further pharma partnerships Engineering and design of next generation laser device Maintenance and Extension of IP portfolio
Key milestones Successful clinical study as part of existing EPIDRUG™ Pharma collaborations mid of 2016 First clinical data with EPIMMUNTM by end of 2016 Pharma partnership for EPIMMUNTM in 2017 Operational profitability in 2019
Exit potential – As a profitable Medtech company with significant growth potential, Pantec
would be an attractive M&A partner for Medtech and pharma companies would be an attractive investment case to go public
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 15
Reinhard Braun, Co-Founder, President and CEO Founder, President and CEO of Pantec Engineering AG Engineering Degree in Electronics
Christof Böhler, PhD, Co-Founder, Exec. Director Business Development CEO at Pantec Biosolutions from 2006 to 2014 PhD in Chemistry and executive degree in International Management
Elmira Lechat, MD, MBA, Medical Director Clinical Services Supervisor/Medical Scientific Expert at Medtronic Assistant at European Respiratory Society
Martin Steiner, PhD, MBA, Business Development EPIMMUNTM
Consultant to biotechnology companies Founder and CEO of two biotechnology companies PhD in Microbiology and Genetics and MBA
Tobias Bächle, Sales Director Senior Regional Sales Manager at Bio Separations GmbH and Macherey-Nagel AG Engineering Degree in Chemistry
Management Team
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 16
Laser platform developed at high quality standards P.L.E.A.S.E. laser platform developed, manufactured and medical CE-marked Established quality management system, ISO certification
Pharma collaborations in place Collaborations with Takeda, Ratiopharm and Oncosynergy (Biotech) actively running First-mover and pioneer in epidermal drug delivery for dermatology and immunotherapy
Strong IP position established Portfolio of patents granted or filed to protect laser device, as well as EPIDRUG™ and EPIMMUN™ Profound technological and application know-how
Promising preclinical data EPIMMUN™ concept successfully demonstrated in several animal studies Activation of relevant immune cells and induction of strong immune response by EPIMMUNTM
Clinical experience Completed clinical studies EPIDRUG™ prove safe, well-tolerated and reproducible laser microporation Ongoing clinical project with Takeda Pharmaceuticals
Strong scientific network Collaborations with leading research groups in different fields of immunotherapy established Several devices sold or rented to academic institutions and biotech companies
Key achievements to date
© Pantec Biosolutions AG, 2015 All rights reserved Confidential slide 17
Investment Considerations
Proprietary, widely-applicable platform technology EPIDRUG™ and EPIMMUN™ are pre-clinically and clinically tested with different substances
for several different indications
Focus on rapidly –growing immunotherapy market Pantec is a leading first-mover and pioneer with proprietary technology and know-how Pantec has extensive network of leading scientific research groups and key opinion leaders Immunotherapy and vaccine market currently more than 75 billion
Management team with extensive know-how and experience Multi-year experience in various senior management roles with biotechnology,
pharmaceutical and medical technology companies
Financially attractive, low-risk investment Low technology risk – clinical experience shows excellent safety profile Existing partnerships with pharma and biotechnology company Platform applicable to a wide range of indications with large market potential
Attractive Exit potential Early break even (i.e. before partnered products enter market) Attractive M&A partner or IPO candidate